PCSK9 Inhibitors and CV Risk Reduction: Understanding the Implications

You are not currently logged in. If you are an NLA Member, you can save time by logging in before visiting this activity.

Click here to take this activity as a Non-Member

No votes yet
Accreditation Information

Content Domain
This activity falls under the following content domain(s):

  • Processing by PCSK9

Learning Objectives
This activity teaches to the following learning objective(s):

  1. Assess the efficacy and safety data for recent trials that examined the cardiovascular impact of PCSK9 inhibitors
  2. Discuss strategies to improve the knowledge, skills or performance of the healthcare team.
  3. Evaluate patient groups in which treatment beyond statins may be needed to decrease lipid-related CV risk
  4. Identify the need for effective therapies for patients with familial hypercholesterolemia

Copyright © 2018 National Lipid Association. All Rights Reserved.

Privacy Policy Terms of Service